Kyverna Therapeutics (KYTX) reported a third-quarter 2026 net loss of $41.9 million, or $0.68 per basic and diluted share, and said it completed submission of its biologics license application for miv-cel in stiff person syndrome.
The company ended September with $170.6 million in cash, cash equivalents and marketable securities. Kyverna said its available cash and amounts available under its amended Oxford Finance loan facility are expected to fund operations into 2028.
- Third-quarter research and development expense was $27.0 million, while general and administrative expense was $15.9 million.
- Kyverna requested priority review from the FDA for miv-cel, also known as mivocabtagene autoleucel or KYV-101, in stiff person syndrome.
- Enrollment in the KYSA-6 Phase 3 trial of miv-cel for generalized myasthenia gravis remains on track for completion in mid-2027.
- The company deprioritized its KYV-102 program to focus on late-stage neurologic indications for miv-cel.
$KYTX Hedge Fund Activity
We have seen 70 institutional investors add shares of $KYTX stock to their portfolio, and 52 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 2,257,729 shares (+257.4%) to their portfolio in Q2 2026, for an estimated $20,116,365
- BALYASNY ASSET MANAGEMENT L.P. removed 1,029,273 shares (-91.5%) from their portfolio in Q2 2026, for an estimated $9,170,822
- AIGH CAPITAL MANAGEMENT LLC added 854,203 shares (+30.6%) to their portfolio in Q3 2026, for an estimated $5,808,580
- MARSHALL WACE, LLP removed 605,512 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $5,395,111
- FMR LLC added 442,328 shares (+460.5%) to their portfolio in Q3 2026, for an estimated $3,007,830
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 421,800 shares (-73.0%) from their portfolio in Q2 2026, for an estimated $3,758,238
- PRICE T ROWE ASSOCIATES INC /MD/ removed 369,264 shares (-23.7%) from their portfolio in Q2 2026, for an estimated $3,290,142
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
